Global plant characterisation and distribution with evolution and climate

Since Arrhenius published seminal work in 1921, research interest in the description of plant traits and grouped characteristics of plant species has grown, underpinning diversity in trophic levels. Geographic exploration and diversity studies prior to and after 1921 culminated in biological, chemical and computer-simulated approaches describing rudiments of growth patterns within dynamic conditions of Earth. This thesis has two parts:- classical theory and multidisciplinary fusion to give mathematical strength to characterising plant species in space and time.Individual plant species occurrences are used to obtain a Species-Area Relationship. The use of both Boolean and logic-based mathematics is then integrated to describe classical methods and propose fuzzy logic control to predict species ordination. Having demonstrated a lack of significance between species and area for data modelled in this thesis a logic based approach is taken. Mamdani and T-S-K fuzzy system stability is verified by application to individual plant occurrences, validated by a multiple interfaced data portal. Quantitative mathematical models are differentiated with a genetic programming approach, enabling visualisation of multi-objective dispersal of plant strategies, plant metabolism and life-forms within the water-energy dynamic of a fixed time-scale scenario. The distributions of plant characteristics are functionally enriched through the use of Gaussian process models. A generic framework of a Geographic Information System is used to visualise distributions and it is noted that such systems can be used to assist in design and implementation of policies. The study has made use of field based data and the application of mathematic methods is shown to be appropriate and generative in the description of characteristics of plant species, with the aim of application of plant strategies, life-forms and photosynthetic types to a global framework. Novel application of fuzzy logic and related mathematic method to plant distribution and characteristics has been shown on a global scale. Quantification of the uncertainty gives novel insight through consequent trophic levels of biological systems, with great relevance to mathematic and geographic subject development. Informative value of Z matrices of plant distribution is increased substantiating sustainability and conservation policy value to ecosystems and human populations dependent upon them for their needs.Key words: sustainability, conservation policy, Boolean and logic-based, fuzzy logic, genetic programming, multi-objective dispersal, strategies, metabolism, life-forms

Rhabdomyoblastic Differentiation in Head and Neck Malignancies Other Than Rhabdomyosarcoma

Rhabdomyosarcoma is a relatively common soft tissue sarcoma that frequently affects children and adolescents and may involve the head and neck. Rhabdomyosarcoma is defined by skeletal muscle differentiation which can be suggested by routine histology and confirmed by immunohistochemistry for the skeletal muscle-specific markers myogenin or myoD1. At the same time, it must be remembered that when it comes to head and neck malignancies, skeletal muscle differentiation is not limited to rhabdomyosarcoma. A lack of awareness of this phenomenon could lead to misdiagnosis and, subsequently, inappropriate therapeutic interventions. This review focuses on malignant neoplasms of the head and neck other than rhabdomyosarcoma that may exhibit rhabdomyoblastic differentiation, with an emphasis on strategies to resolve the diagnostic dilemmas these tumors may present. Axiomatically, no primary central nervous system tumors will be discussed.info:eu-repo/semantics/publishedVersio

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Prospects for Sustainability in Human\u2013Environment Patterns: Dynamic Management of Common Resources

Models envisaged by policy makers and sustainability scientists cooperatively produce tools with desired practical implications. Models presented in the volume are summarized, with existing policy methods for resource management and Global perspective for resource planning methods in context. Models are discussed \ufb01rstly in the framework of learning environments as an opportunity to test and practice sustainability, combining different tools from models, case studies, and scenarios. Sustainability asks for a multi-scale pragmatics; key elements of the multiple scale approach representing common ground in existing practice and frontier research have been identi\ufb01ed. Two case studies are presented as a metasummary of the issues presented in the book, being Rural South Asia (with special reference to India), and analysis of mega-diverse countries in Latin America, with special focus on Ecuador. India\u2019s case study offers an account of policies implemented by the Ministry of Rural Development (MRD) and the Ministry of Tribal Affairs (MTA) since 1947, creating sustainable models for biodiversity and natural resource management. To comprehend the methods of resource sustainability usage in the present era, while enhancing resource utilization capacity of traditional practices, a tribal (indigenous communities) village\u2014\u2018Ajanta\u2019 (Western India)\u2014is elaborated upon. The Latin America case study focuses on declinations of the buen vivir (good living) concept and the debate between putting nature to the service of a nation (extractivism) and Yasunization, the neologism coined in Ecuador by a civil society seeking territorial innovation combining community engagement, biodiversity conservation, and environmental justice. Through the macro-cosmic to micro-cosmic approach, a \u2018north-south\u2019, \u2018developed versus developing regions\u2019 dichotomy and possible areas of accord for resource management and sustainability in the global perspective is presented

Preface: From the coordinating editor

This edited volume focuses on how we can protect our environment and enhance environmental sustainability when faced with changes and pressures imposed by our expansive needs. The volume unites multiple subject areas within sustainability, enabling the techniques and philosophy in the chapters to be applied to research areas in environmental science, plant sciences, energy, biodiversity and conservation. The chapters from expert contributors cover topics such as mathematical modelling tools used to monitor diversity of plant species, and the stability of ecosystem services such as biogeochemical cycling. Empirical research presented here also brings together mathematical developments in the important fields of robotics including kinematics, dynamics, path planning, control, vision, and swarmanoids. Through this book readers will also discover about rainfall-runoff modelling which will give them a better idea of the effects of climate change on the sustainability of water resources at the watershed scale. Modelling approaches will also be examined that maximize readers insights into the global problem of energy transition, i.e. the switch to an energy production system using renewable resources only. Collective and discrete insights are made to assist with synergy which should progress well beyond this book. Insight is also given to assist policy formations, development and implementations. The book has a strong multi-disciplinary nature at its core, and will appeal to both generalist readers and specialists in information technology, mathematics, biology, physics, chemistry and environmental sciences

Source, timing, frequency and flux of ice-rafted detritus to the Northeast Atlantic margin, 30-12 ka: testing the Heinrich precursor hypothesis

Increased fluxes of ice-rafted detritus (IRD) from European ice sheets have been documented some 1000–1500 years before the arrival of Laurentide Ice Sheet (LIS)-sourced IRD during Heinrich (H) events. These early fluxes have become known as ‘precursor events’, and it has been suggested that they have mechanistic significance in the propagation of H events. Here we present a re-analysis of one of the main cores used to generate the precursor concept, OMEX-2K from the Goban Spur covering the last 30 ka, in order to identify whether the British–Irish Ice Sheet (BIIS) IRD fluxes occur only as precursors before H layers. IRD characterization and planktonic foraminiferal δ18O measurements constrained by a new age model have enabled the generation of a continuous record of IRD sources, timing, frequency and flux, and of local contemporary hydrographic conditions. The evidence indicates that BIIS IRD precursors are not uniquely, or mechanistically, linked to H events, but are part of the pervasive millennial-scale cyclicity. Our results support an LIS source for the IRD comprising H layers, but the ambient glacial sections are dominated by assemblages typical of the Irish Sea Ice Stream. Light isotope excursions associated with H events are interpreted as resulting from the melting of the BIIS, with ice-sheet destabilization attributed to eustatic jumps generated by LIS discharge during H events. This positive-feedback mechanism probably caused similar responses in all circum-Atlantic ice-sheet margins, and the resulting gross freshwater flux contributed to the perturbation of the Atlantic Meridional Overturning Circulation during H events

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

BACKGROUND: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2. METHODS: We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 × 1010 viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 neutralisation assays (a 50% plaque reduction neutralisation assay [PRNT50]; a microneutralisation assay [MNA50, MNA80, and MNA90]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo interferon-γ enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606. FINDINGS: Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0·05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493-1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted following a second dose (639 EU, 360-792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA80 and in 35 (100%) participants when measured in PRNT50. After a booster dose, all participants had neutralising activity (nine of nine in MNA80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly with antibody levels measured by ELISA (R2=0·67 by Marburg VN; p<0·001). INTERPRETATION: ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme. FUNDING: UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and the German Center for Infection Research (DZIF), Partner site Gießen-Marburg-Langen

Mandatory continuing professional development requirements: what does this mean for Australian nurses

Background This paper presents a discussion related to the recent decision in Australia to introduce mandatory Continuing Professional Development (CPD) for nurses. Historically there has been international debate surrounding mandatory CPD requirements; this debate is ongoing as Australian nurses face a diverse range of CPD offerings from a variety of providers. Discussion The purpose of this paper is to examine how mandatory CPD requirements for national nursing registration in Australia have evolved and to present an analysis of what this will mean for Australian nurses. What is yet to be determined is how to measure professional development and the effectiveness of professional development education. This is important to the international community with consensus in the literature that professional development is linked to ongoing education. Contradicting arguments are presented about whether this professional development should be mandatory. Summary Presenting a contemporary discussion about the current and potential impact of mandatory CPD requirements for nurses, this discussion paper utilises the case of Australia’s current national policy and CPD operation to examine the choices that nurses make in order to fulfil their legislative requirements. Additional arguments are presented about the barriers nurses face in undertaking CPD. The quest for effective CPD is complex and should incorporate different situations for nurses and individual learning styles